Alivus Life Sciences Limited (Formerly Glenmark Life Sciences Limited), a leading developer and manufacturer of select, high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, announced its financial results for the quarter and nine months ended December 31, 2024.

Revenue from operations for Q3FY25 reached Rs. 641.8 crore, a growth of 12.0% YoY and 26.6% QoQ. For 9MFY25, revenue from operations was Rs. 1,737.3 crore.

For Q3FY25, EBITDA was at Rs. 200.8 crore, a growth of 15.2% YoY and 40.5% QoQ. EBITDA margins were at 31.3%, up 90 bps YoY and 310 bps QoQ. EBITDA for 9MFY25 was at Rs. 508.6 crore while EBITDA margins stood at 29.3%.

PAT for the quarter stood at Rs. 137 crore and PAT margins were at 21.3%. For 9MFY25, the company recorded PAT of Rs. 343.8 crore with PAT margins of 19.8%.

During 9MFY25, the company generated a strong free cash flow of Rs. 183.8 crore leading to Cash and Cash Equivalents (including short term investments) of Rs. 499.3 crore as of 31 December 2024. 

Commenting on the company’s performance, Dr. Yasir Rawjee, MD & CEO, Alivus Life Sciences Limited said, “The start of the new year marks a notable shift for us as we transition to Alivus Life Sciences. I am pleased to report that our Q3 performance reflects this renewed energy, with growth across both GPL and Non-GPL segments. Geographically, regions like India, Europe, ROW and Japan contributed to the growth. Our quest for high-quality, innovative solutions and scalability continues, in order to build a sustainable business over the long term.”

Tushar Mistry, CFO, Alivus Life Sciences Limited said, “Our emphasis on achieving quality growth has delivered encouraging outcomes with highest ever quarterly revenue at Rs. 6,418 Mn. This translated to steady gross margins at ~56%, while our EBITDA grew by 15.2% YoY, underscoring our ability to cater a diversified product range while maintaining stringent cost efficiency."